Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
复制标题
DOI：
10.1093/cei/uxad013
复制
发表时间：
2023-03-24
影响因子：
4.6
通讯作者：
中科院分区：
文献类型：
--
作者：
初始剂量系列之后的免疫应答轨迹决定了疫苗有效性随时间的下降。在这里，我们报告了在没有感染的情况下，ChAdOx 1 nCoV-19/AZD 1222两次给药方案后一年内免疫应答的维持情况，并探讨了感染后抗体的衰减。两种低剂量ChAdOx 1 nCoV-19疫苗（两种低剂量）（P = 0.0006）的总加标特异性IgG抗体滴度低于2种标准剂量（批准剂量）或低剂量后标准剂量疫苗方案。第一剂和第二剂之间的间隔时间越长，抗体滴度越高（P < 0.0001）;然而，没有证据表明抗体衰减的轨迹因间隔时间或疫苗剂量而异，在第三剂ChAdOx 1 nCoV-19后，IgG抗体滴度的衰减遵循类似的轨迹。感染后样本的趋势相似，最初的反应迅速衰减，但此后可测量的反应具有良好的持久性。在两次ChAdOx 1 nCov-19给药后，抗体数据的外推证明了建模的抗体衰减速率缓慢，表明抗体滴度至少保持2年。这些数据表明，在两剂ChAdOx 1 nCov-19后，持续的免疫应答可能会对严重疾病和住院治疗产生积极影响。两剂ChAdOx 1 nCov-19（AZD 1222）给药后的总加标特异性IgG抗体应答持续良好1年。建模表明滴度至少保持2年。因此，两剂ChAdOx 1 nCov-19可能会对严重疾病和住院治疗产生积极影响。
The trajectory of immune responses following the primary dose series determines the decline in vaccine effectiveness over time. Here we report on maintenance of immune responses during the year following a two-dose schedule of ChAdOx1 nCoV-19/AZD1222, in the absence of infection, and also explore the decay of antibody after infection. Total spike-specific IgG antibody titres were lower with two low doses of ChAdOx1 nCoV-19 vaccines (two low doses) (P = 0.0006) than with 2 standard doses (the approved dose) or low dose followed by standard dose vaccines regimens. Longer intervals between first and second doses resulted in higher antibody titres (P < 0.0001); however, there was no evidence that the trajectory of antibody decay differed by interval or by vaccine dose, and the decay of IgG antibody titres followed a similar trajectory after a third dose of ChAdOx1 nCoV-19. Trends in post-infection samples were similar with an initial rapid decay in responses but good persistence of measurable responses thereafter. Extrapolation of antibody data, following two doses of ChAdOx1 nCov-19, demonstrates a slow rate of antibody decay with modelling, suggesting that antibody titres are well maintained for at least 2 years. These data suggest a persistent immune response after two doses of ChAdOx1 nCov-19 which will likely have a positive impact against serious disease and hospitalization. Total spike-specific IgG antibody responses after two doses of ChAdOx1 nCov-19 (AZD1222) persist well for 1 year. Modelling suggesting titres are well maintained for at least 2 years. Therefore, two doses of ChAdOx1 nCov-19 will likely have a positive impact against serious disease and hospitalization.
登录
查看更多内容
DOI：
10.1016/s0140-6736(20)32661-1
发表时间：
2021-01-09
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Clemens SAC;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Collins AM;Colin-Jones R;Cutland CL;Darton TC;Dheda K;Duncan CJA;Emary KRW;Ewer KJ;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Goodman AL;Green CM;Green CA;Heath PT;Hill C;Hill H;Hirsch I;Hodgson SHC;Izu A;Jackson S;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Lawrie AM;Lelliott A;Libri V;Lillie PJ;Mallory R;Mendes AVA;Milan EP;Minassian AM;McGregor A;Morrison H;Mujadidi YF;Nana A;O'Reilly PJ;Padayachee SD;Pittella A;Plested E;Pollock KM;Ramasamy MN;Rhead S;Schwarzbold AV;Singh N;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Tarrant R;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;Watson MEE;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
影响因子：
64.5
作者：
Payne RP;Longet S;Austin JA;Skelly DT;Dejnirattisai W;Adele S;Meardon N;Faustini S;Al-Taei S;Moore SC;Tipton T;Hering LM;Angyal A;Brown R;Nicols AR;Gillson N;Dobson SL;Amini A;Supasa P;Cross A;Bridges-Webb A;Reyes LS;Linder A;Sandhar G;Kilby JA;Tyerman JK;Altmann T;Hornsby H;Whitham R;Phillips E;Malone T;Hargreaves A;Shields A;Saei A;Foulkes S;Stafford L;Johnson S;Wootton DG;Conlon CP;Jeffery K;Matthews PC;Frater J;Deeks AS;Pollard AJ;Brown A;Rowland-Jones SL;Mongkolsapaya J;Barnes E;Hopkins S;Hall V;Dold C;Duncan CJA;Richter A;Carroll M;Screaton G;de Silva TI;Turtle L;Klenerman P;Dunachie S;PITCH Consortium
通讯作者：
PITCH Consortium
DOI：
10.1056/nejmoa2105290
发表时间：
2021-12-16
期刊：
The New England journal of medicine
影响因子：
--
作者：
Falsey AR;Sobieszczyk ME;Hirsch I;Sproule S;Robb ML;Corey L;Neuzil KM;Hahn W;Hunt J;Mulligan MJ;McEvoy C;DeJesus E;Hassman M;Little SJ;Pahud BA;Durbin A;Pickrell P;Daar ES;Bush L;Solis J;Carr QO;Oyedele T;Buchbinder S;Cowden J;Vargas SL;Guerreros Benavides A;Call R;Keefer MC;Kirkpatrick BD;Pullman J;Tong T;Brewinski Isaacs M;Benkeser D;Janes HE;Nason MC;Green JA;Kelly EJ;Maaske J;Mueller N;Shoemaker K;Takas T;Marshall RP;Pangalos MN;Villafana T;Gonzalez-Lopez A;AstraZeneca AZD1222 Clinical Study Group
通讯作者：
AstraZeneca AZD1222 Clinical Study Group
DOI：
10.1084/jem.20220732
发表时间：
2022-08-01
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
通讯作者：
--
DOI：
10.1016/s1473-3099(21)00330-3
发表时间：
2021-11
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Hyams C;Marlow R;Maseko Z;King J;Ward L;Fox K;Heath R;Tuner A;Friedrich Z;Morrison L;Ruffino G;Antico R;Adegbite D;Szasz-Benczur Z;Garcia Gonzalez M;Oliver J;Danon L;Finn A
通讯作者：
Finn A